Maternal use of proton pump inhibitors (PPI) during pregnancy is associated with an increased risk for cardiac birth defects
(3 May 2010: VIDYYA MEDICAL NEWS SERVICE) -- The use of common anti-reflux medications during pregnancy may be associated with cardiac birth defects, according to a new study from the University of Pennsylvania School of Medicine.
More than half of all women who become pregnant suffer from gastroesophageal reflux (GERD), better known as heartburn, which can be hard to control during pregnancy. Often symptoms start early in pregnancy when the fetus is most vulnerable to the effects of medications, which can lead to birth defects. Because of the prevalence of GERD during pregnancy, investigators sought to determine the safety of a popular class of anti-reflux medications, proton pump inhibitors (PPIs), on the developing fetus.
Usually, physicians treat pregnancy-related GERD with conservative measures such as advising patients to eat smaller meals, but frequently, these methods are ineffective, which is why physicians are increasingly prescribing PPIs. Since PPIs are relatively new to the market, not much is known about their safety during pregnancy. For example, omeprazole, the most commonly used PPI, is designated as a class C by FDA, which means that animal studies show adverse effects to the fetus, yet there are no adequate studies in humans since those that have been conducted had too small a sample to draw any definitive conclusions.
Researchers performed a nested case-control study within The Health Improvement Network database and looked at medical records from pregnant women in the U.K. from 2000 to 2008. They identified which pregnancies resulted in birth defects and compared the maternal PPI use of these cases with matched pregnancies that did not result in a birth defect.
"We found that PPI use during pregnancy was associated with a doubling in the risk of cardiac birth defects in the newborn," said lead researcher Andrew D. Rhim, MD, the Sir William Osler MD Fellow in Gastroenterology at the University of Pennsylvania School of Medicine. "The lack of association between maternal PPI use and other types of birth defects makes it less likely that our findings are due to confounding."
Dr. Rhim cautioned that cardiac birth defects associated with PPI use, such as ventricular septal defect and Tetralogy of Fallot, are relatively rare. Thus, a pregnant woman taking PPIs should not necessarily assume this will automatically cause birth defects in her baby. He added that patients and physicians need to weigh the possible risks and benefits of anti-reflux treatment on a case-by-case basis, since many women will develop heartburn in pregnancy that can be severe and result in poor quality of life. Of all of the PPIs that researchers looked at, omeprazole was associated with the greatest increase in the risk for having a baby with a cardiac birth defect.
He said the data from the study suggest that H2 receptor antagonists (H2RA), another anti-reflux medication that has been proven to be effective and are considered safe in pregnancy, could be tried before PPIs to minimize potential risks. Then, if symptoms are not controlled by H2RAs, PPIs could be considered next.
Dr. Rhim will present these data on Monday, May 3 at 4:15 p.m. CT in 291, Ernest N. Morial Convention Center.
Digestive Disease Week® 2010 (DDW®) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the AGA Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes place May 1 – May 5, 2010 in New Orleans, LA. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology.
Return to Vidyya Medical News Service for 3 May 2010
© Vidyya. All rights reserved.
Information appearing on the Vidyya Medical News Service is not intended as a substitute for professional medical care. Seek professional medical help and follow your health care provider's advice.
Interested in subscribing to our daily e-mail newsletter? Send an email to [email protected] with the word subscribe in the subject field.